Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma (Q42929917)

11 November 2017

Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma (English)

1 reference

11 November 2017

1 reference

Keith Stockerl-Goldstein

10

object named as

Keith Stockerl-Goldstein

1 reference

11 November 2017

19

Andrzej J Jakubowiak

1 reference

11 November 2017

1

Dominik Dytfeld

1 reference

11 November 2017

Jagoda Jasielec

2

1 reference

11 November 2017

Kent A Griffith

3

1 reference

11 November 2017

Daniel Lebovic

4

1 reference

11 November 2017

David H Vesole

5

1 reference

11 November 2017

Sundar Jagannath

6

1 reference

11 November 2017

Ammar Al-Zoubi

7

1 reference

11 November 2017

Tara Anderson

8

1 reference

11 November 2017

Kristen Detweiler-Short

9

1 reference

11 November 2017

Asra Ahmed

11

1 reference

11 November 2017

Terri Jobkar

12

1 reference

11 November 2017

Diane E Durecki

13

1 reference

11 November 2017

Kathryn McDonnell

14

1 reference

11 November 2017

Melissa Mietzel

15

1 reference

11 November 2017

Daniel Couriel

16

1 reference

11 November 2017

Mark Kaminski

17

1 reference

11 November 2017

Ravi Vij

18

1 reference

11 November 2017

27 June 2014

1 reference

11 November 2017

1 reference

11 November 2017

99

1 reference

11 November 2017

e162-4

1 reference

11 November 2017

9

1 reference

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival

11 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562550

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562550

Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562550

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562550

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562550

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562550

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562550

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562550

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562550

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562550

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m

1 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24972772

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24972772

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3324/HAEMATOL.2014.110395

1 reference

11 November 2017

1 reference

11 November 2017

1 reference